Hosted on MSN2mon
1.5 billion people at risk: New tablet promises to battle parasitic worms with greater efficacyTo address these gaps, the EDCTP-funded STOP consortium tested a fixed-dose co-formulation (FDC) of albendazole and ivermectin in the ALIVE trial, which took place in Ethiopia, Kenya, and Mozambique.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback